Physician profile
Michael B Parrott
NPI 1265641534
$13,479.00
in general payments reported to CMS, 2019-2025
20 companies · $227 in 2025
The $227 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,260 · 2020: $841 · 2021: $5,141 · 2022: $423 · 2023: $195 · 2024: $392 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $664 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $664.15 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $9,936.05 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $800.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $709.25 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $588.01 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $388.26 | 2022-2025 | Vabysmo |
| Carl Zeiss Meditec, INC. | $205.52 | 2019 | |
| Cardinal Health 110 LLC | $150.00 | 2024 | |
| Medtronic USA, INC. | $147.74 | 2019 | |
| Apellis Pharmaceuticals, INC. | $126.02 | 2022-2025 | Syfovre |
| Mallinckrodt Enterprises LLC | $120.57 | 2019 | |
| Spark Therapeutics, INC. | $95.29 | 2022 | |
| Astellas Pharma US INC | $50.14 | 2023-2024 | Izervay |
| Genentech, INC. | $45.49 | 2019 | |
| Halozyme INC | $32.71 | 2019-2021 | |
| Biogen, INC. | $28.49 | 2024 | Byooviz |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $25.54 | 2022 | |
| Alimera Sciences, INC. | $15.32 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.60 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Parrott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.